Skip to main content

How long does Opdivo prolong life and what’s its success rate?

Medically reviewed by Carmen Pope, BPharm. Last updated on April 3, 2024.

What's the overall survival rate and duration of survival in patients treated with Opdivo? How many people respond to treatment with Opdivo - what's the objective response rate (ORR)?

Official answer

by Drugs.com

Opdivo (nivolumab) is an immunotherapy used to treat a wide variety of cancer types. How long treatment with this monoclonal antibody prolongs or extends life depends on the type and stage of cancer it is used to treat.

In some situations Opdivo will prolong life for longer when used in combination with other medications, while in others it is better used alone. In other types of cancer it provides no survival benefit over existing therapies, but patients may be more likely to respond to treatment with Opdivo than to treatment it was compared against.

How long Opdivo prolongs life and how successful it is at treating patients with cancer is typically measured in clinical trials by looking at overall rates of patient survival, and duration of patient survival/response or progression-free survival. How successful Opdivo is as a treatment is also measured in clinical trials by looking at the number of patients who respond to the therapy with either complete or partial responses, which is known as the objective response rate (ORR)

The table below outlines by cancer type how long Opdivo prolongs survival and how many patients respond to treatment according to the results of key clinical trials used to gain approval of this drug.

Cancer Type
(Trial name)		 Survival rates and duration of survival Percentage of people that had a complete or partial response to treatment
(Objective response rate, ORR)
Melanoma - completely resected stage IIB or IIC melanoma (Checkmate-76K)

Outcomes

  • Opdivo reduced the risk of recurrence, new primary melanoma, or death by 58% compared to placebo (HR: 0.42; 95% CI: 0.30-0.59; P<0.0001)
  • At one year, the recurrence-free survival (RFS) rate was 89% (95% CI: 86-92) for Opdivo versus 79% (95% CI: 74-84) for placebo
  • One-year RFS rates by stage for patients who received Opdivo were 93% (95% CI: 89–95) in stage IIB versus 84% (95% CI: 77–89) with placebo, and 84% (95% CI: 78–88) in stage IIC versus 72% (95% CI: 62–80) with placebo
Melanoma - unresectable or metastatic
(CheckMate-037)		 Ongoing response
  • Opdivo: 87% had ongoing responses ranging from 2.6+ to 10+ months
  • Opdivo: 13/38 had ongoing responses of ≥ 6 months


Median duration of overall survival

  • Opdivo: 15.7 months (95% CI: 12.9, 19.9)
    vs
    Dacarbazine or paclitaxel + carboplatin: 14.4 months (95% CI: 11.7, 18.2) (HR 0.95; 95.54% CI: 0.73, 1.24)
 Objective response rate
  • Opdivo: 31·7% (95% CI 23·5-40·8)
    vs
    Dacarbazine or paclitaxel + carboplatin: 10·6%, 95% CI 3·5-23·1)
Melanoma - previously untreated
(CheckMate-066)		 Overall survival rate
  • Opdivo: 72.9% (95% CI 65.5-78.9)
    vs
    Dacarbazine: 42.1% (95% CI 33.0-50.9)
 Objective response rate
  • Opdivo: 40% (95% CI, 33.3 to 47.0)
    vs
    Dacarbazine: 13.9% (95% CI, 9.5 to 19.4)
Melanoma - previously untreated, unresectable or metastatic
(CheckMate-067)		 Median duration of overall survival
  • Opdivo + Yervoy: 60+ months
    vs
    Opdivo: 36.9 months
    vs
    Yervoy: 19.9 months

Overall survival rate

  • Opdivo + Yervoy: 52%
    vs
    Opdivo: 44%
    vs
    Yervoy: 26%
 Objective response rate
  • Opdivo + Yervoy: 58%
    vs
    Opdivo: 45%
    vs
    Yervoy: 19%
Melanoma - adjuvant treatment for completely resected Stage IIIB/C or Stage IV disease
(CheckMate-238)		 Recurrence free survival (minimum 4 years’ follow up)
  • Opdivo: 51·7% (95% CI 46·8-56·3)
    vs
    Yervoy: 41.2% (95% CI36.4-45.9)
Non-small cell lung cancer - metastatic with PD-L1 expression level of ≥ 1%
(CheckMate-227)		 Median duration of overall survival
  • Opdivo + Yervoy: 17.1 months (95% CI 15.0-20.1)
    vs
    Chemotherapy: 14.9 months (95% CI 12.7-16.7)

Overall survival rate

  • Opdivo: 40% at 2 years
    vs
    Chemotherapy: 32.8%
Non-small cell lung cancer - first-line treatment of metastatic or recurrent disease
(CheckMate-9LA)		 Median duration of overall survival
(minimum 12.7 months’ follow up)
  • Opdivo + Yervoy + chemotherapy: 15.6 months
    vs
    Chemotherapy: 10.9 months (HR 0.66, 95% CI: 0.55–0.80)

Overall survival rate

  • Opdivo + Yervoy + chemotherapy: 63% at 1 year
    vs
    Chemotherapy: 47%
 Overall response rate
  • Opdivo + Yervoy: 38% (95% CI 33-43)
    vs
    Chemotherapy: 25% (95% CI 21-30)
Non-small cell lung cancer - second-line treatment of metastatic disease
(CheckMate-017, CheckMate-057)		 Overall survival rate
(minimum 3 years’ follow up)
  • Opdivo: 17% (95% CI 14-21)
    vs
    Docetaxel: 8% (95% CI 6-11)


Patients with liver metastasis also had improved overall survival rates when treated with Opdivo compared with docetaxel
Non-small cell lung cancer - neoadjuvant treatment of resectable disease
(CheckMate-816)

Median event-free survival
(minimum 21 months’ follow up)

  • Opdivo + platinum doublet chemotherapy: 31.6 months (95% CI 30.2-not reached)
    vs
    Platinum-doublet chemotherapy: 20.8 months (95% CI 14.0-26.7)
    (HR 0.63, 95% CI 0.45, 0.87)

Overall survival rate

  • Overall survival was not statistically significant between Opdivo + platinum doublet chemotherapy recipients and patients who received platinum doublet chemotherapy alone
Malignant pleural mesothelioma
(CheckMate-743)		 Median duration of overall survival
  • Opdivo + Yervoy: 18.1 months (95% CI 16.8, 21.5)
    vs
    Chemotherapy: 14.1 months (95% CI 12.5, 16.2)

Median progression-free survival

  • Opdivo + Yervoy: 6.8 months (95% CI 5.6, 7.4)
    vs
    Chemotherapy: 7.2 months (95% CI 6.9, 8.1)
Renal cell carcinoma - advanced
(CheckMate-025)		 Median duration of overall survival
  • Opdivo: 25.8 months (95% CI 22.2-29.8)
    vs
    Everolimus: 19.7 months (95% CI 17.6-22.1)

Progression-free survival was also improved in the Opdivo group

 Objective response rate
  • Opdivo: 23%
    vs
    Everolimus: 4%
Renal cell carcinoma - previously untreated
(CheckMate-214)		 Overall survival rate
  • Opdivo + Yervoy: 75% (95% CI 70-80) at 18 months
    vs
    Sutent (sunitinib) 60% (95% CI 55-65)

Median duration of overall survival

  • Opdivo + Yervoy: not reached
    vs
    Sutent: 26 months (P ﹤0.001)
Progression-free survival
  • Opdivo + Yervoy: 11.6 months
    vs
    Sutent: 8.4 (P = 0.03)
 Objective response rate
  • Opdivo + Yervoy: 42%
    vs
    Sutent (sunitinib) 27% (P ﹤0.001)
Renal cell carcinoma - advanced, previously untreated
(CheckMate-9ER)		 Overall survival rate
  • Overall survival was not reached in either the Opdivo + Cabometyx (cabozantinib) group or the Sutent group during the 18.1 months median follow up period
Median duration of response
  • Opdivo + Cabometyx: 20.2 months (95% CI 17.3, not reached)
    vs
    Sutent: 11.5 months (95% CI 8.3, 18.4)
Median progression-free survival
  • Opdivo + Cabometyx: 16.6 months
    vs
    Sutent: 8.3 months (P <0.0001)
 Objective response rate
  • Opdivo + Cabometyx: 55.7%
    vs
    Sutent 27.1% (P ﹤0.0001)
Classical Hodgkin lymphoma
(CheckMate-205)		 Median duration of response
  • Opdivo: 16.6 months (95% CI 13.2-20.3)

Median progression-free survival

  • Opdivo: 14.7 months (95% CI 11.3-18.5)
Of the evaluable patients in the trial treated past conventional disease progression, 61% had stable or further reduced target tumor burdens		 Objective response rate
  • Opdivo: 69% across all three treatment groups (95% CI 63-75)
Squamous cell carcinoma of the head and neck - recurrent or metastatic disease
(CheckMate-141)		 Overall survival rate
  • Opdivo: 16.9% at 24 months
    vs
    Docetaxel, methotrexate or Erbitux (cetuximab): 6%

Overall survival benefit was not impacted by PD-L1 expression of human papilloma virus (HPV) status.

Median duration of overall survival
  • Opdivo: 7.5 months (95% CI 5.5, 9.1) at the interim analysis
    vs
    Docetaxel, methotrexate or Erbitux (cetuximab): 5.1 month (95% CI 4.0, 6.0)
 Objective response rates were similar between the two treatment groups.
Urothelial Carcinoma - locally advanced or metastatic disease
(CheckMate-275)		 Median overall survival
(minimum 37 months’ follow up)
  • Opdivo: 8.6 months (95% CI 6.1-11.3)

Median progression-free survival

  • Opdivo: 1.9 months (95% CI 1.9-2.3)
 Objective response rate
  • Opdivo: 20.7% (16.1-26.1)
Urothelial Carcinoma - adjuvant therapy in high-risk patients following surgery
(CheckMate-274)		 Median disease-free survival
(intention to treat population)
  • Opdivo: 20.8 months (95% CI 16.5-27.6)
    vs
    Placebo: 10.8 months (95% CI 8.3-13.9)

(PD-L1≥1% population)

  • Opdivo: not reached (95% CI 21.2-not estimable)
    vs
    Placebo: 8.4 months (95% CI 5.6-21.2)

Unresectable or Metastatic Urothelial Carcinoma - in combination with cisplatin and gemcitabine (CheckMate-901)

Median overall survival

  • Opdivo + cisplatin and gemcitabine followed by Opdivo monotherapy: 21.7 months versus 18.9 months with cisplatin/gemcitabine alone (95% CI 0.63-0.96; p=0.0171)

Objective response rate

  • Opdivo + cisplatin + gemcitabine: 57.6% (95% CI: 51.8-63.2)
    • vs
  • Cisplatin + gemcitabine: 43.1% (95% CI:37.5-48.9)
Colorectal cancer - microsatellite instability-high or mismatched repair deficient metastatic disease
(CheckMate-142)		 Proportion of responders with ≥ 12 months response duration
  • Opdivo: 82%
    vs
    Opdivo + Yervoy: 77%
 Overall response rate
(minimum of 27.5 and 33.7 months’ follow up, respectively)
  • Opdivo: 60% (95% CI 50, 69)
    vs
    Opdivo + Yervoy: 38% (95% CI 27, 50)
Hepatocellular carcinoma
(CheckMate-040)		 Overall survival rate
  • Opdivo + Yervoy every 3 weeks (4 doses) then Opdivo every 2 weeks (Arm A): 61% (95% CI 46-72) at 12 months and 48% (95% CI 32-61) at 24 months

Medial duration of overall survival

  • Opdivo + Yervoy every 3 weeks (4 doses) then Opdivo every 2 weeks (Arm A): Not reached in patients with complete or partial responses, 14.5 months (95% CI 8.4-29.6) in patients with stable disease and 8.3 months (95% CI 6.6-10.8)
 Objective response rate
  • Opdivo + Yervoy every 3 weeks (4 doses) then Opdivo every 2 weeks (Arm A): 32% (95% CI 20-47)
Esophageal squamous cell cancer
(ATTRACTION-3)		 Median duration of overall survival
  • Opdivo: 10.9 months (95% CI 9.2-13.3)
    vs
    Docetaxel or paclitaxel: 8.4 months (95% CI 7.2-9.9)

Median progression-free survival

  • Opdivo: 1.7 months (95% CI 1.5, 2.7)
    vs
    Docetaxel or paclitaxel: 3.4 months (95% CI 3.0, 4.2)
 Overall response rate
  • Opdivo: 19.3% (95% CI 13.7, 26.0)
    vs
    Docetaxel or paclitaxel: 21.5% (95% CI 15.4, 28.8)
Esophageal squamous cell cancer - first-line treatment of unresectable advanced or metastatic disease
(CheckMate-648)

Median duration of overall survival
All randomized patients

  • Opdivo + cisplatin + fluorouracil: 13.2 months (95% CI 11.1-15.7)
    vs
    Opdivo + Yervoy: 12.8 months (95% CI 11.3-15.5)
    vs
    Cisplatin + fluorouracil: 10.7 months (95% CI 9.4-11.9)

Median progression-free survival

  • There was no statistically significant difference in median progression-free survival among the groups when the results from all randomized patients were included
 Overall response rate
All randomized patients
  • Opdivo + cisplatin + fluorouracil: 47.4% (95% CI 41.8-53.0)
    vs
    Opdivo + Yervoy: 27.7% (95% CI 22.9-32.9)
    vs
    Cisplatin + fluorouracil: 26.9% (95% CI 22.1-32.0)
Gastric cancer - previously untreated advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma
(CheckMate-649)

Median duration of overall survival
Patients whose tumours expressed PD-L1 CPS ≥ 5

  • Opdivo + mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) or CapeOX (capecitabine and oxaliplatin): 14.4 months (95% CI 13.1, 16.2)
    vs
    mFOLFOX6 or CapeOX: 11.1 months (95% CI 10.0, 12.1), (p<0.0001)

All randomized patients

  • Opdivo + mFOLFOX6 or CapeOX: 13.8 months (95% CI 12.6, 14.6)
    vs
    mFOLFOX6 or CapeOX: 11.6 months (95% CI 10.9, 12.5), (p=0.0002)

Median progression-free survival
Patients whose tumours expressed PD-L1 CPS ≥ 5

  • Opdivo + mFOLFOX6 or CapeOX: 7.7 months (95% CI 7.0, 9.2)
    vs
    mFOLFOX6 or CapeOX: 6.0 months (95% CI 5.6, 6.9), (p<0.0001)
 Overall response rate
Patients whose tumours expressed PD-L1 CPS ≥ 5
  • Opdivo + mFOLFOX6 or CapeOX: 237 (50%) (95% CI 46, 55)
    vs
    mFOLFOX6 or CapeOX: 138 (38%) (95% CI 34, 43)

All randomized patients

  • Opdivo + mFOLFOX6 or CapeOX: 370 (47%) (95% CI 43, 50)
    vs
    mFOLFOX6 or CapeOX: 293 (37%) (95% CI 34, 40)
Gastric cancer - completely resected esophageal or gastroesophageal junction cancer
(CheckMate-577)		 Median disease free survival
  • Opdivo: 22.4 months (95% CI 16.6, 34.0)
    vs
    Placebo: 11.0 months (95% CI 8.3, 14.3) (p=0.0003)

Related Questions

References
  • Food and Drug Administration (FDA). Opdivo. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125554s128lbl.pdf 
  • Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384. doi:10.1016/S1470-2045(15)70076-8.
  • Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330. doi:10.1056/NEJMoa1412082.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836.
  • Ascierto PA, Del Vecchio M, Mandalá M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465-1477. doi:10.1016/S1470-2045(20)30494-0.
  • Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-2031. doi:10.1056/NEJMoa1910231.
  • Reck M, Ciuleanu T-E, Cobo Dols M, et al. Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology 2020 38:15_suppl, 9501-9501.
  • Vokes EE, Ready N, Felip E, et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959-965. doi:10.1093/annonc/mdy041.
  • Ready NE, Ott PA, Hellmann MD, et al. Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. J Thorac Oncol. 2020;15(3):426-435. doi:10.1016/j.jtho.2019.10.004.
  • Food and Drug Administration (FDA). FDA approves nivolumab and ipilimumab for unresectable malignant pleural mesothelioma. October 2, 2020. Available from: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-and-ipilimumab-unresectable-malignant-pleural-mesothelioma. 
  • Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial [published online ahead of print, 2020 Jul 16]. Cancer. 2020;10.1002/cncr.33033. doi:10.1002/cncr.33033.
  • Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi:10.1056/NEJMoa1712126.
  • Choreiri TK, Powles T, Burotto M, et al. 696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325.
  • Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial [published correction appears in J Clin Oncol. 2018 Sep 10;36(26):2748]. J Clin Oncol. 2018;36(14):1428-1439. doi:10.1200/JCO.2017.76.0793.
  • Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol. 2018;81:45-51. doi:10.1016/j.oraloncology.2018.04.008.
  • Galsky MD, Saci A, Szabo PM, et al. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res. 2020;26(19):5120-5128. doi:10.1158/1078-0432.CCR-19-4162.
  • Yau T, Kang YK, Kim TY, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial [published online ahead of print, 2020 Oct 1]. JAMA Oncol. 2020;6(11):e204564. doi:10.1001/jamaoncol.2020.4564.
  • Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol. 2019 Nov;20(11):e613]. Lancet Oncol. 2019;20(11):1506-1517. doi:10.1016/S1470-2045(19)30626-6.
  • Moehler M, Shitara K, Garrido M, et al. LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): first results of the CheckMate 649 study. Ann Oncol. 2020; 31(suppl 4): S1191. doi:10.1016/j.annonc.2020.08.2296.
  • Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med. 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125.
  • Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma [published correction appears in N Engl J Med. 2021 Aug 26;385(9):864]. N Engl J Med. 2021;384(22):2102-2114. doi:10.1056/NEJMoa2034442.
  • Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. doi:10.1056/NEJMoa2202170.
  • Doki Y, Ajani JA, Kato K, et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med. 2022;386(5):449-462. doi:10.1056/NEJMoa2111380.
  • Long GV, Del Vecchio M, Weber J, et al. Adjuvant therapy with nivolumab versus placebo in patients with resected stage IIB/C melanoma (CheckMate 76K). Presented at: Society for Melanoma Research 2022 International Congress; October 17-20, 2022; Edinburgh, Scotland.

Read next

Opdivo stays in your system for a very long time, up to 3 to 4 months (100 to 125 days). This is based on the half-life of Opdivo, which is 25 days. The half-life is the time it takes for half of a drug to be removed from the body, and experts have agreed it takes 4 to 5 half-lives for a drug to be completely removed from the body. This calculates out to 100 to 125 days for Opdivo. This means that side effects can still occur because of Opdivo a few months after you stop taking the drug. Continue reading

Pembrolizumab and nivolumab are both prescription medications used to treat various types of cancers, including solid tumors and blood cancers. They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments. Continue reading

Opdivo (nivolumab) is an immunotherapy used to treat a variety of cancer types, including melanoma. Durable responses to treatment have been observed following discontinuation of Opdivo therapy. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer